Acute Respiratory Distress Syndrome Clinical Trial
Official title:
Airway Pressure Release Ventilation in Acute Lung Injury
The purpose of this study is to compare airway pressure release ventilation (APRV) to
conventional mechanical ventilation (MV) in patients with acute lung injury (ALI) to
determine if APRV can reduce agitation, delirium, and requirements for sedative medications.
We will also compare markers of inflammation in the blood and lung to determine if APRV
reduces ventilator-induced lung injury (VILI), compared to conventional mechanical
ventilation.
The proposed study is a randomized, crossover trial. We plan to enroll 40 patients with ALI
and randomize to APRV or conventional MV for 24 hours. After this time the patients will be
switched to the alternative mode of ventilation (MV or APRV) for another 24 hours. To assess
breathing comfort, at the end of each 24-hour period we will measure the amounts of sedative
and analgesic medications used. We will also measure the concentrations of markers of
inflammation in the blood and lung as measures of VILI. Finally, throughout the study we
will compare the adequacy of gas exchange with APRV compared to conventional MV.
Acute respiratory failure is common in patients with acute lung injury. MV re-establishes
adequate gas exchange; it allows time for administration of antibiotics, for the host's
immune system to fight infections, and for natural healing. Approximately 60% of ALI
patients survive to hospital discharge (1). However, conventional approaches to MV in ALI
frequently cause dysynchrony between a patient's spontaneous respiratory efforts and the
ventilator's respiratory cycle (2;3). Dysynchrony causes discomfort, anxiety, and agitation.
To manage dysynchrony, physicians frequently prescribe large doses of sedative and analgesic
medications. These medications contribute to delirium and sleep deprivation during the
critical illness, and may delay weaning from MV and discharge from the intensive care unit
(2;4). They may also contribute significantly to neuromuscular and neurocognitive sequelae
after recovery from ALI (5;6). Moreover, MV may itself cause additional lung injury
(ventilator-induced lung injury, VILI) which could, paradoxically, delay or prevent recovery
from respiratory failure in some ALI patients (7;9).
Airway pressure release ventilation (APRV) is a mode of MV that is designed to reduce
patient-ventilator dysynchrony and VILI. It differs from most other modes of MV in that it
allows patients to breathe spontaneously at any time, independent of the ventilator's cycle.
This feature may improve breathing comfort by minimizing patient-ventilator dysynchrony.
Improving comfort and reducing agitation may ultimately curtail the use of sedative and
analgesic medications. Since a substantial proportion of ventilation results from the
patient's spontaneous efforts independent of the ventilator cycle, the frequency of
mechanically assisted breaths can be reduced. This may reduce VILI from the cyclic
opening-closing of alveoli and small bronchioles that results from assisted MV breaths.
Another feature of APRV that distinguishes it from other modes of MV is that it applies a
sustained high pressure during inspiration and a brief period of lower pressure during
exhalation. This approach may maximize and maintain alveolar recruitment throughout the
ventilatory cycle while limiting high airway pressures, thus further reducing VILI.
Moreover, spontaneous contractions of the diaphragm during APRV may open dependent
atelectatic lung regions, improving ventilation-perfusion (V/Q) matching and gas exchange.
However, these potential advantages of APRV are unproven.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Recruiting |
NCT05535543 -
Change in the Phase III Slope of the Volumetric Capnography by Prone Positioning in Acute Respiratory Distress Syndrome
|
||
Completed |
NCT04695392 -
Restore Resilience in Critically Ill Children
|
N/A | |
Terminated |
NCT04972318 -
Two Different Ventilatory Strategies in Acute Respiratory Distress Syndrome Due to Community-acquired Pneumonia
|
N/A | |
Completed |
NCT04534569 -
Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF)
|
||
Completed |
NCT04078984 -
Driving Pressure as a Predictor of Mechanical Ventilation Weaning Time on Post-ARDS Patients in Pressure Support Ventilation.
|
||
Completed |
NCT04451291 -
Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure
|
N/A | |
Not yet recruiting |
NCT06254313 -
The Role of Cxcr4Hi neutrOPhils in InflueNza
|
||
Not yet recruiting |
NCT04798716 -
The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19
|
Phase 1/Phase 2 | |
Withdrawn |
NCT04909879 -
Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome
|
Phase 2 | |
Not yet recruiting |
NCT02881385 -
Effects on Respiratory Patterns and Patient-ventilator Synchrony Using Pressure Support Ventilation
|
N/A | |
Terminated |
NCT02867228 -
Noninvasive Estimation of Work of Breathing
|
N/A | |
Completed |
NCT02545621 -
A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
|
||
Withdrawn |
NCT02253667 -
Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients
|
N/A | |
Completed |
NCT02232841 -
Electrical Impedance Imaging of Patients on Mechanical Ventilation
|
N/A | |
Completed |
NCT01504893 -
Very Low Tidal Volume vs Conventional Ventilatory Strategy for One-lung Ventilation in Thoracic Anesthesia
|
N/A | |
Completed |
NCT02889770 -
Dead Space Monitoring With Volumetric Capnography in ARDS Patients
|
N/A | |
Withdrawn |
NCT01927237 -
Pulmonary Vascular Effects of Respiratory Rate & Carbon Dioxide
|
N/A | |
Completed |
NCT02814994 -
Respiratory System Compliance Guided VT in Moderate to Severe ARDS Patients
|
N/A | |
Completed |
NCT01680783 -
Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure
|
N/A |